手术联合<sup>125</sup>I粒子治疗口腔涎腺腺样囊性癌患者可能作用机制分析

doi:10.3969/j.issn.1006-6233.2022.01.07

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1197 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的:探讨手术联合¹²⁵I粒子近距离置入治疗对口腔涎腺腺样囊性癌(ACC)患者相关生长因子及临床疗效的影响。方法:选择2016年4月至2018年3月收治的符合条件的ACC患者80例,采用随机数字表法分为观察组41例和对照组39例。对照组行单纯手术治疗,观察组采用手术联合¹²⁵I粒子近距离置入治疗。随访3年,比较两组临床疗效;治疗前、治疗6个月,采用酶联免疫法检测血清血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFEG)、基质金属蛋白酶-9(MMP-9)含量。结果:随访3年,与对照组比较,观察组ACC患者缓解率、控制率高于对照组,差异有统计学意义(82.93% vs 58.97%,92.86% vs 74.36%)(χ²=5.598,4.932,P<0.05)。治疗6个月,与对照组比较,观察组ACC患者血清VEGF、bFEG、MMP-9含量低于对照组,差异有统计学意义[(238.54±36.25 vs 266.46±32.23)pg/m,(215.42±34.25 vs 276.26±36.12)pg/mL,(493.24±24.36 vs 524.12±30.43)pg/mL](t=3.634,7.732,5.023,P<0.05)。结论:手术联合¹²⁵I粒子治疗有助于提高ACC患者临床疗效,其作用机制可能与降低血清VEGF、bFEG、MMP-9含量有关。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：腺样囊性癌, 碘-125粒子, 血管内皮生长因子, 碱性成纤维细胞生长因子, 基质金属蛋白酶-9

Abstract：Objective: To study the related growth factors and clinical efficacy of surgery combined ¹²⁵I brachytherapy patients with nts with oral salivary adenoid cystic carcinoma(ACC). Methods: 86 patients with ACC from April 2016 to March 2018 were divided into observation group (41 cases) and control group (39 cases). The control group had surgery, and the observation group had surgery combined with ¹²⁵I brachytherapy. The clinical efficacy were compared between two groups in the three-year follow-up. Before treatment and 6 months after treatment, serum related growth factors were compared between two groups. Results: In the three-year follow-up, the observation group remission rate and control rate were higher than those of the control group (82.93% vs 58.97%, 92.86% vs 74.36%)(χ²=5.598, 4.932, P<0.05). 6 months after therapy, observation group had serum VEGF, bFEG, MMP-9 lower than control group [(238.54±36.25 vs 266.46±32.23)pg/m,(215.42±34.25 vs 276.26±36.12)pg/mL,(493.24±24.36 vs 524.12±30.43)pg/mL](t=3.634, 7.732, 5.023, P<0.05). Conclusion: Surgery combined with ¹²⁵I brachytherapy can improve clinical efficacy of ACC patients, and its mechanism may be related to reducing serum VEGF, BFEG and MMP-9.

Key words： Adenoid cystic carcinoma ¹²⁵I Vascular endothelial growth factor Basic fibroblast growth factor Matrix metalloprteinases-9

基金资助:河北省张家口市科学技术和地震局课题,(编号:1821056D)

引用本文:

李立恒, 周军, 张敏, 王芹, 安峰, 张丽娟, 汪佳, 张凡. 手术联合¹²⁵I粒子治疗口腔涎腺腺样囊性癌患者可能作用机制分析[J]. 河北医学, 2022, 28(1): 33-36.
LI Liheng, et al. The Possible Mechanism of Surgery Combined with ¹²⁵I Brachytherapy for Patients with Oral Salivary Adenoid Cystic Carcinoma. HeBei Med, 2022, 28(1): 33-36.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2022.01.07 或 http://www.hbyxzzs.cn/CN/Y2022/V28/I1/33

[1] 李燕,邓文英,李宁,等.头颈部腺样囊性癌的临床特征治疗策略和预后[J].中华肿瘤杂志,2019,41(12):932~936.
[2] Reshko L,Khan Z,Sowards K,et al.Squamous cell and adenoid cystic carcinoma collision tumor of the soft palate treated with surface mold brachytherapy [J].Cureus,2020,12(3):e7297.
[3] 高雅,张杰,刘树铭,等.¹²⁵I粒子近距离治疗在局部晚期腮腺腺样囊性癌的应用[J].中华放射医学与防护杂志,2021,41(1):9~12.
[4] 韩静,高献争,魏建国,等.原发性腺样囊性癌59例临床病理学特征及预后因素分析[J].中华病理学杂志,2019,48(3):204~208.
[5] Wang HF,Wang SS,Zheng M,et al.Hypoxia promotes vasculogenic mimicry formation by vascular endothelial growth factor A mediating epithelial-mesenchymal transition in salivary adenoid cystic carcinoma [J].Cell Prolif,2019,52(3):e12600.
[6] Tabatabai ZL,Auger M,Kurtyca DF,et al.Performance characteristics of adenoid cystic carinomaof the salivary glands n fine-needle aspirates:results from the collgeg of american pathologists nongynecologic cytology program [J].Arch Pathol Lab Med,2015,139(12):1525~1530.
[7] Eisenhauer EA,Therasse P,Boqaerts J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J].Eur Cancer,2009,45(2):228~247.
[8] Li C,Liu SM,Zheng L,et al.Comparison of outcomes using radiotherapy or brachytherapy after resection of primary adenoid cystic carcinoma in oral and maxillofacial regions [J].Brachytherapy,2021,20(1):171~177.
[9] 马廷耀,陈晓红.头颈部腺样囊性癌的手术治疗方案抉择[J].中华转移性肿瘤杂志,2021,4(1):59~61.
[10] 葛胜优,周凯,孔钰,等.数字化导航引导下¹²⁵I精确植入治疗9例颅底腺源性恶性肿瘤的疗效评价[J].中国口腔颌面外科杂志,2020,18(3):272~277.
[11] Xu N,Zheng L,Wu WJ,et al.Definitive ¹²⁵I Brachytherapy of Locally Advanced Adenoid Cystic Carcinoma Involving the Skull Base With Satisfying Efficacy and Safety [J].J Oral Maxillofac Surg,2019,77(10):2143~2153.
[12] 李聪,刘树铭,郑磊,等.手术联合¹²⁵I粒子治疗口腔颌面腺样囊性癌的疗效与相关预后因素分析[J].北京大学学报(医学版),2019,51(1):49~52.
[13] Shamloo N,Taghavi N,Yazdani F,et al.Evaluation of VEGF expression correlates with COX-2 expression in pleomorphic adenoma,mucoepidermoid carcinoma and adenoid cystic carcinoma [J].Dent Res (Isfahan),2020,17(2):100~106.
[14] Freitas VS,Santos JND,de Andrade Santos PP,et al.Expression of matrix metalloproteinases (MMPs-2,-7,-9,and -26) and tissue inhibitors of metalloproteinases (TIMPs-1 and -2) in pleomorphic adenomas and adenoid cystic carcinomas [J].Eur Arch Otorhinolaryngol,2018,275(12):3075~3082.
[15] 王璐.联合检测血清E-cad、MMP-2及VEGF的表达对涎腺腺样囊性癌的诊断价值[J].贵州医科大学学报,2017,42(2):241~243.
[16] 朱栩,白忠诚,汤楚华,等.¹²⁵I对涎腺腺样囊性癌移植瘤中MMP-2和VEGF的表达影响[J].中华老年口腔医学杂志,2018,16(3):147~150.
[17] 郭洁,康巍林,张显利,等.CT引导下¹²⁵I粒子切缘置入对肝癌切除术患者残余病灶的效果观察[J].中国肿瘤临床与康复,2020,27(12):1491~1494.